Anzeige
Meldung des Tages: Warum dieser €9,5-Millionen-Explorer kurz vor dem Bohrstart plötzlich extrem spannend wird

Genprex News

Aktie
WKN:  A41L3N ISIN:  US3724463027 US-Symbol:  GNPX Branche:  Biotechnologie Land:  USA
1,96 $
+0,00 $
0,00%
1,7074 € 02.03.26
Depot/Watchlist
Marktkapitalisierung *
1,90 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Genprex News

28.05.25 - PR Newswire
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting PR Newswire
07.05.25 - PR Newswire
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes PR Newswire
06.05.25 - PR Newswire
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma PR Newswire
30.04.25 - PR Newswire
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual ...
29.04.25 - PR Newswire
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting PR Newswire
28.04.25 - PR Newswire
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma PR Newswire
24.04.25 - PR Newswire
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting PR Newswire
22.04.25 - PR Newswire
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings PR Newswire
26.03.25 - PR Newswire
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting PR Newswire
25.03.25 - PR Newswire
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions PR Newswire

Newssuche

Videos

newspaper
16.03.26 0,00%
Technical Trading: 82 Prozent Trefferquote
S&P 500 Long Typ: Open End Turbo WKN: VG93RW Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »